Dr Nave is a founding partner of Brandon Capital Partners and Chief Executive Officer of the Medical Research Commercialisation Fund. Brandon Capital is a leading Australian life science investment firm with over $500M in assets currently under management. Chris was previously Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia, where he led the commercialization of technologies developed at the Baker and Alfred Hospital. Chris was also Manager of the Biotechnology Team at Melbourne Ventures, the commercialisation company of the University of Melbourne. In 2014, Chris was awarded the Australian Biotechnology Johnson & Johnson Industry Leadership Award, for his contribution to the industry. Chris is currently a Director of Global Kinetics Corporation, PolyActiva, OccuRx Therapeutics, QueOncology and Athena Medicines. Chris has a first-class Honours degree in Science and he has completed the Private Equity and Venture Capital Program at Harvard Business School, Boston, MA.